Use of Stool-derived Eukaryotic RNA (seRNA) to Noninvasively Assess Patients with IBD

Time: 9:30 am
day: Day One


  • Improving detection, selection, and monitoring of treatment response for patients with IBD
  • Leveraging technology across a variety of biomarker types, including RNA expression, allele frequencies of expressed RNA variants, and protein concentrations
  • User-friendly platform allows periodic monitoring with improved patient engagement and compliance